Acorda Therapeutics, Inc.

OTCPK:ACOR.Q Stock Report

Market Cap: US$37.4k

Acorda Therapeutics Valuation

Is ACOR.Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ACOR.Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ACOR.Q's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ACOR.Q's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACOR.Q?

Key metric: As ACOR.Q is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ACOR.Q. This is calculated by dividing ACOR.Q's market cap by their current revenue.
What is ACOR.Q's PS Ratio?
PS Ratio0.0002x
SalesUS$115.66m
Market CapUS$37.39k

Price to Sales Ratio vs Peers

How does ACOR.Q's PS Ratio compare to its peers?

The above table shows the PS ratio for ACOR.Q vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.1x
ATNX.Q Athenex
0.001xn/aUS$131.7k
PKBO Peak Bio
6.9xn/aUS$1.6m
ENDV Endonovo Therapeutics
1.2xn/aUS$317.5k
ISCO International Stem Cell
0.09xn/aUS$960.5k
ACOR.Q Acorda Therapeutics
0.0002xn/aUS$37.4k

Price-To-Sales vs Peers: ACOR.Q is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (0.8x).


Price to Sales Ratio vs Industry

How does ACOR.Q's PS Ratio compare vs other companies in the US Biotechs Industry?

126 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.9x21.4%
ACOR.Q Acorda Therapeutics
0.0002xn/aUS$37.39k
BIIB Biogen
2.4x1.3%US$23.13b
MRNA Moderna
3.2x6.7%US$16.80b
ACOR.Q 0.0xIndustry Avg. 9.9xNo. of Companies126PS01632486480+
126 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.9x28.3%
ACOR.Q Acorda Therapeutics
0.0002xn/aUS$37.39k
No more companies

Price-To-Sales vs Industry: ACOR.Q is good value based on its Price-To-Sales Ratio (0x) compared to the US Biotechs industry average (11.3x).


Price to Sales Ratio vs Fair Ratio

What is ACOR.Q's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACOR.Q PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.0002x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ACOR.Q's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies